Syngene International Ltd
NSE: SYNGENE · Healthcare Research, Analytics & Technology · sector
₹359.85NSE close 2026-10-26
Key numbers
Market cap₹14,527 cr
Price₹359.85
52w high / low₹679 / ₹344
P/E65.4xSector median 27.9x
P/B3.0xSector median 3.0x
Book value₹119.9
Dividend yield0.35%Sector median 0.34%
ROE4.6%Sector median 6.1%
ROCE7.0%Sector median 9.8%
OPM19.8%Sector median 8.4%
Debt / equity0.00xSector median 0.01x
EV/EBITDA18.6xSector median 14.8x
Interest cover7.2x
Current ratio1.38x
Sales growth 3y+5.4%Sector median +7.2%
Profit growth 3y-12.0%Sector median -13.6%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 9 companies in Healthcare Research, Analytics & Technology (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹1,289 cr vs borrowings ₹9 cr (FY26): cash is higher (net cash).
- Borrowings fell in each of the last 3 years (₹575 cr → ₹9 cr).
- Operating profit covered interest 7.2x in the last 12 months.
- Operating cash flow was below net profit in 0 of the last 5 years.
- Net loss in 1 of the last 8 quarters.
- Revenue was higher than a year earlier in 2 of the last 4 quarters.
- Other income was 35% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹359.85 on 2026-10-26: -47.0% from the 52-week high, +4.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹928.30 · low ₹347.40
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 891 | 944 | 1,018 | 874 | 911 | 917 | 1,036 | 736 |
| EBITDA | 245 | 284 | 344 | 206 | 200 | 139 | 297 | 77 |
| OPM % | 27.5% | 30.1% | 33.8% | 23.6% | 21.9% | 15.1% | 28.7% | 10.5% |
| Other income | 16 | 18 | 19 | 18 | 15 | 15 | 22 | 25 |
| Net profit | 106 | 131 | 183 | 87 | 67 | 15 | 148 | -9 |
| EPS (₹) | 2.64 | 3.27 | 4.56 | 2.16 | 1.67 | 0.37 | 3.68 | -0.22 |
| Revenue YoY | +2.2% | -2.8% | +1.8% | -15.8% | ||||
| Profit YoY | -36.8% | -88.6% | -19.3% | -110.4% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2,604 | 3,193 | 3,489 | 3,642 | 3,739 | 3,600 |
| EBITDA | 765 | 934 | 1,003 | 1,074 | 842 | 713 |
| Net profit | 396 | 464 | 510 | 496 | 317 | 221 |
| EPS (₹) | 9.94 | 11.59 | 12.71 | 12.35 | 7.87 | 5.50 |
| Revenue growth | +22.6% | +9.3% | +4.4% | +2.6% | -3.4% | |
| Profit growth | +17.3% | +9.8% | -2.7% | -36.2% | -56.4% | |
| Dividend / share (₹) | – | 0.50 | 0.50 | 1.25 | 1.25 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +5.4% | +11.3% | -3.4% |
| Net profit | -12.0% | -4.8% | -56.4% |
| EPS | -12.1% | -5.0% | – |
| Share price | – | -33.7% (2y) | -41.3% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 3,618 | 4,258 | 4,727 | 4,839 |
| Borrowings | – | 575 | 142 | 120 | 9 |
| Cash & equivalents | – | 1,356 | 1,077 | 1,398 | 1,289 |
| Total assets | – | 5,831 | 6,152 | 6,796 | 7,055 |
| Fixed assets | – | 2,383 | 2,378 | 2,323 | 2,545 |
| Capital work in progress | – | 177 | 837 | 1,261 | 1,040 |
| Investments | – | 94 | 35 | 36 | 285 |
| Receivables | – | 529 | 442 | 527 | 509 |
| Inventory | – | 333 | 238 | 156 | 141 |
| Payables | – | 258 | 256 | 352 | 348 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 581 | 824 | 1,042 | 1,168 | 915 |
| Cash from investing | -612 | -656 | -496 | -745 | -860 |
| Cash from financing | -31 | -342 | -551 | -142 | -215 |
| Capex | 476 | 518 | 511 | 770 | 368 |
| Free cash flow | 105 | 305 | 531 | 398 | 547 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 12.8% | 12.0% | 10.5% | 6.5% |
| ROCE % | – | 15.2% | 15.2% | 14.7% | 9.5% |
| Debtor days | – | 61 | 46 | 53 | 50 |
| Inventory days | – | 141 | 94 | 60 | 56 |
| Payable days | – | 109 | 100 | 136 | 138 |
| Cash conversion cycle (days) | – | 93 | 40 | -23 | -32 |
| Working capital days | – | 141 | 85 | 89 | 58 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 52.59% |
| FIIs | 10.14% |
| DIIs | 29.30% |
| of which Mutual funds | 27.10% |
| of which Insurance | 2.10% |
| Public (non-institutions) | 7.56% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 52.74% | 52.74% | 52.68% | 52.68% | 52.68% | 52.68% | 52.59% | 52.59% |
| Promoter group | % |
|---|---|
| Biocon Limited | 52.32% |
| Biocon Limited Employee Welfare Trust | 0.26% |
| Kiran Mazumdar Shaw | 0.01% |
| Ravi Rasendra Mazumdar | 0.00% |
| Biocon Research Limited | 0.00% |
| DEV Mazumdar | 0.00% |
| Public holders above 1% | % |
|---|---|
| Nippon Life India Trustee Ltd-a/c Nippon India PHA | 8.00% |
| ICICI Prudential MNC Fund | 6.82% |
| DSP Nifty 500 Index Fund | 4.71% |
| SBI Nifty Smallcap 250 ETF | 3.10% |
| Life Insurance Corporation of India | 1.78% |
| Government of Singapore | 1.16% |
| Mirae Asset Focused Fund | 1.05% |
| Tata India Innovation Fund | 1.02% |
1,34,008 shareholders. Pledged: – of promoter shares.
Peers in Healthcare Research, Analytics & Technology
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SYNGENE | ₹14,527 cr | 65.4x | 3.0x | 4.6% | 7.0% | 19.8% | +5.4% | 0.35% |
| INDGN | ₹14,472 cr | 36.0x | 4.6x | 13.9% | 17.4% | 16.2% | – | 0.33% |
| SUVEN | ₹6,917 cr | – | 11.7x | -100.5% | -59.5% | -4,155.5% | -19.3% | – |
| VIMTALABS | ₹2,185 cr | 27.4x | 4.8x | 19.1% | 23.5% | 34.3% | +8.9% | 0.20% |
| BI | ₹189 cr | 4.3x | 1.0x | 2.3% | 7.0% | 8.4% | +274.4% | – |
| TAKE | ₹154 cr | 12.1x | 5.0x | 49.8% | 20.1% | -2.0% | -34.1% | – |
| NOVELIX | ₹141 cr | 31.7x | 3.0x | 11.3% | 8.8% | 3.1% | +411.3% | – |
| JSTL | ₹102 cr | 28.5x | 1.4x | 6.1% | 9.8% | 20.5% | +19.4% | 0.97% |
| ADESHWAR | ₹23 cr | 18.0x | 0.9x | 5.5% | 10.2% | 4.9% | -12.0% | – |
All 9 companies in Healthcare Research, Analytics & Technology →
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-06-25 | Dividend | Dividend - Rs 1.25 Per Share |
| 2025-06-27 | Dividend | Dividend - Rs 1.25 Per Share |
| 2024-06-28 | Dividend | Dividend - Rs 1.25 Per Share |
| 2023-06-30 | Dividend | Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.75 Per Share |
| 2022-06-30 | Dividend | Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.50 Per Share |
| 2021-07-13 | Other | Annual General Meeting |
| 2019-07-16 | Dividend | Dividend - Rs 0.50 Per Share |
| 2019-06-11 | Bonus | Bonus 1:1 |
| 2018-07-17 | Dividend | Dividend Re - Re 1 Per Share |
| 2017-07-20 | Dividend | Dividend - Rs 1/- Per Share |
| 2016-03-17 | Dividend | Interim Dividend - Re 1/- Per Share (Purpose Revised) |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Contract research, development and manufacturing services: Provide scientific solutions through integrated research, development and manufacturing
| Sector | Healthcare |
| Industry | Healthcare Research, Analytics & Technology |
| Sub-industry | Healthcare Research, Analytics & Technology |
| Symbol | SYNGENE |
| BSE code | 539268 |
| ISIN | INE398R01022 |
| Face value | ₹10.0 |
| Incorporated | 1993-11-18 |
| Website | www.syngeneintl.com |
| Plants (India / abroad) | 9 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.